The observed HbA1c reduction in this study (1.2%) is slightly lower than the reductions reported in the SUSTAIN clinical trials, where a 1.0 mg dose of OW sema reduced HbA1c by 1.5% to 1.8% after 30 to 56 weeks as shown by Meier in a meta-analysis of the SUSTAIN trials
In general, long acting GLP-1 RAs are better at lowering A1c levels compared to short acting agents (15,282)
For example, researchers have used mass spectrometry imaging to map metabolite distribution in brain tissue from mice
However, robust randomized controlled trials specifically in RA populations remain limited, and current evidence does not support GLP-1 drugs as monotherapy for RA
This enhanced glucose disposal improves both fasting and post-meal blood sugar control over time
Over the counter cold remedies are acceptable in the absence of the above symptoms